Relationships Among Antibodies Against Extractable Nuclear Antigens, Antinuclear Antibodies, and Autoimmune Diseases in a Brazilian Public Hospital

Overview

Journal Autoimmune Dis

Publisher Wiley

Date 2018 Oct 27

PMID 30364021

Citations 6

Authors

Fernanda Weyand Banhuk

Bruna Correa Pahim

Alex Sandro Jorge

Rafael Andrade Menolli

Affiliations

Soon will be listed here.

Abstract

One characteristic of autoimmune diseases (ADs) is the production of autoantibodies for extractable nuclear autoantigens, which may aid in the discrimination of the different types of autoimmune diseases and is related to different antinuclear antibody (ANA) patterns. The present study verified the profile of patient samples tested for extractable nuclear antigens (ENA) antibodies in a public hospital and correlated the ENA results with ANA patterns and patient diagnoses. The study reviewed data in the medical records of patients who underwent anti-ENA tests at a public hospital in the West of the State of Paraná from February 2011 to January 2017. Patients were classified according to age, ethnicity, gender, anti-ENA test results, ANA results, and the presence or absence of AD. Thirty-six (20.9%) samples of the 172 anti-ENA tests were positive, seven (4.1%) samples were undetermined, and 129 (75%) exhibited negative results. The ANA reagent was found in 84.3% of the anti-ENA-positive samples. The anti-SSA/Ro autoantibody exhibited the highest frequency in the group, 41.7% (15/36). The most common pattern was nuclear fine speckled, which was found in 24.3% of the samples. The association results indicated a significant relationship between ANA titer and diagnosis in the anti-ENA- and ANA-positive patients. The anti-ENA-negative patients were diagnosed with an AD in 35% (45/129) of the cases, and 75% (27/36) of the anti-ENA-positive patients were diagnosed with an AD. Systemic lupus erythematosus and scleroderma were the most common pathologies in the antigen-positive patients. The anti-ENA test is a good marker to aid in the complex clinical diagnosis of patients with autoimmune diseases.

Citing Articles

International Consensus on ANA Patterns (ICAP) Classification Tree Revisited: A Single Centre Report on Four Nuclear Patterns from a Tertiary Care Centre in India.

Ranjan A, Ahmad S, Kumar S, Patra P, Kumar A, Prakash J EJIFCC. 2025; 36(1):37-49.

PMID: 40061060 PMC: 11886623.

The Discovery of New Antibody in Autoimmune Disease Using a Novel Approach of Coombs Test Based on Flow Cytometry Method.

Ullah A, Ding X, Qi X, Liu H J Clin Lab Anal. 2025; 39(3):e25148.

PMID: 39829383 PMC: 11821728. DOI: 10.1002/jcla.25148.

ANA-specific antibodies, ANA patterns, anti-ds-DNA results, and clinical diagnosis: a laboratory and clinical audit.

Anis S, Fatima A, Abdul Jabbar S, Arain T Immunol Res. 2022; 71(2):267-275.

PMID: 36456720 DOI: 10.1007/s12026-022-09347-z.

The antinuclear antibody HEp-2 indirect immunofluorescence assay: a survey of laboratory performance, pattern recognition and interpretation.

Tebo A, Schmidt R, Kadkhoda K, Peterson L, Chan E, Fritzler M Auto Immun Highlights. 2021; 12(1):4.

PMID: 33640027 PMC: 7916270. DOI: 10.1186/s13317-020-00146-w.

Cerebellar ataxia as a primary manifestation of neuropsychiatric systemic lupus erythematosus.

Sy M, Reyes N, Zamora G, Fernandez M BMJ Case Rep. 2021; 14(2).

PMID: 33542005 PMC: 7868266. DOI: 10.1136/bcr-2020-236825.

References

Mahler M, Parker T, Peebles C, Andrade L, Swart A, Carbone Y . Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012; 39(11):2104-10. DOI: 10.3899/jrheum.120598. View

Shang Y, Han S, Li J, Ren Q, Song F, Chen H . The clinical feature of Behçet's disease in Northeastern China. Yonsei Med J. 2009; 50(5):630-6. PMC: 2768236. DOI: 10.3349/ymj.2009.50.5.630. View

Sanchez-Guerrero J, Lew R, Fossel A, Schur P . Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 1996; 39(6):1055-61. DOI: 10.1002/art.1780390626. View

Almeida Gonzalez D, de Leon A, Rodriguez Perez M, Diaz B, Gonzalez Hernandez A, Garcia D . Efficiency of different strategies to detect autoantibodies to extractable nuclear antigens. J Immunol Methods. 2010; 360(1-2):89-95. DOI: 10.1016/j.jim.2010.06.013. View

Cho J, Gregersen P . Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med. 2011; 365(17):1612-23. DOI: 10.1056/NEJMra1100030. View

Kim J, Ihm C, Sin D, Ihm M, Sim S . [Detection of anti-ENA and anti-dsDNA antibodies using line immunoassay in systemic autoimmune diseases]. Korean J Lab Med. 2008; 28(5):353-61. DOI: 10.3343/kjlm.2008.28.5.353. View

Phan T, Wong R, Adelstein S . Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol. 2002; 9(1):1-7. PMC: 119916. DOI: 10.1128/cdli.9.1.1-7.2002. View

Venables P, Erhardt C, Maini R . Antibodies to extractable nuclear antigens in rheumatoid arthritis: relationship to vasculitis and circulating immune complexes. Clin Exp Immunol. 1980; 39(1):146-53. PMC: 1537954. View

Wu H, Zeng J, Yin J, Peng Q, Zhao M, Lu Q . Organ-specific biomarkers in lupus. Autoimmun Rev. 2017; 16(4):391-397. DOI: 10.1016/j.autrev.2017.02.011. View

10.

Nagele E, Han M, Acharya N, DeMarshall C, Kosciuk M, Nagele R . Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One. 2013; 8(4):e60726. PMC: 3617628. DOI: 10.1371/journal.pone.0060726. View

11.

Dahle C, Skogh T, Aberg A, Jalal A, Olcen P . Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun. 2004; 22(3):241-8. DOI: 10.1016/j.jaut.2003.12.004. View

12.

Hoffman I, Peene I, Veys E, De Keyser F . Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem. 2002; 48(12):2171-6. View

13.

Craig W, Ledue T . The relationship between antinuclear antibody data and antibodies against extractable nuclear antigens in a large laboratory cohort. Clin Chem Lab Med. 2011; 50(3):497-502. DOI: 10.1515/CCLM.2011.790. View

14.

Sharmin S, Ahmed S, Abu Saleh A, Rahman F, Choudhury M, Hassan M . Association of Immunofluorescence pattern of Antinuclear Antibody with Specific Autoantibodies in the Bangladeshi Population. Bangladesh Med Res Counc Bull. 2015; 40(2):74-8. DOI: 10.3329/bmrcb.v40i2.25225. View

15.

Ma W, Chang C, Gershwin M, Lian Z . Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J Autoimmun. 2017; 83:95-112. DOI: 10.1016/j.jaut.2017.07.003. View

16.

Peene I, Van Ael W, Vandenbossche M, Vervaet T, Veys E, de Keyser F . Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies. Clin Rheumatol. 2000; 19(4):291-5. DOI: 10.1007/s100670070048. View

17.

Bossuyt X, Frans J, Hendrickx A, Godefridis G, Westhovens R, Marien G . Detection of anti-SSA antibodies by indirect immunofluorescence. Clin Chem. 2004; 50(12):2361-9. DOI: 10.1373/clinchem.2004.035964. View

18.

Provost T . Anti-Ro(SSA) and anti-La(SSB) antibodies in lupus erythematosus and Sjögren's syndrome. Keio J Med. 1991; 40(2):72-7. DOI: 10.2302/kjm.40.72. View

19.

Targoff I . Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000; 12(6):475-81. DOI: 10.1097/00002281-200011000-00001. View

20.

Nell V, Machold K, Stamm T, Eberl G, Heinzl H, Uffmann M . Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005; 64(12):1731-6. PMC: 1755298. DOI: 10.1136/ard.2005.035691. View